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Abstract  
Apoptosis resistance contributes to treatment failure in colorectal cancer (CRC). New 
treatments that reinstate apoptosis competency have potential to improve patient outcome but 
require predictive biomarkers to target them to responsive patient populations. Inhibitor of 
apoptosis proteins (IAPs) suppress apoptosis, contributing to drug resistance; IAP antagonists 
such as TL32711 have therefore been developed. We developed a systems biology approach 
for predicting response of CRC cells to chemotherapy and TL32711 combinations in vitro 
and in vivo. CRC cells responded poorly to TL32711 monotherapy in vitro; however, co-
treatment with 5-Fluorouracil (5-FU) and oxaliplatin enhanced TL32711-induced apoptosis. 
Notably, cells from genetically identical populations responded highly heterogeneously, with 
caspases being activated both upstream and downstream of mitochondrial outer membrane 
permeabilisation (MOMP). These data, combined with quantities of key apoptosis regulators 
were sufficient to replicate in vitro cell death profiles by mathematical modelling. In vivo, 
apoptosis protein expression was significantly altered, and mathematical modelling for these 
conditions predicted higher apoptosis resistance that could nevertheless be overcome by 
combination of chemotherapy and TL32711. Subsequent experimental observations agreed 
with these predictions, and the observed effects on tumour growth inhibition correlated 
robustly with apoptosis competency. We therefore obtained insights into intracellular signal 
transduction kinetics and their population-based heterogeneities for chemotherapy/TL32711 
combinations and provide proof-of-concept that mathematical modelling of apoptosis 
competency can simulate and predict responsiveness in vivo. Being able to predict response 
to IAP antagonist-based treatments on the background of cell-to-cell heterogeneities in the 
future might assist in improving treatment stratification approaches for these emerging 
apoptosis-targeting agents. 
 
 
Key words: Apoptosis, colorectal cancer, chemotherapy, systems biology, IAP, SMAC.
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Introduction 
Stage III and high risk stage II colon cancer patients receive adjuvant 5-fluorouracil (5-FU)-
based chemotherapy often combined with oxaliplatin. However, 5-FU/oxaliplatin treatment 
in stage III benefits only 15%-20% of patients (1). Moreover, 5-year OS rates are less than 
6% for stage IV metastatic CRC (mCRC) patients treated primarily with 5-FU-based 
regimens. Current targeted treatments such as anti-EGFR therapies are approved in the 
metastatic setting only for a subset of patients (RAS, BRAF wild-type) and are ineffective in 
the adjuvant setting (2,3). Since pre-existing or acquired resistance to apoptosis significantly 
contributes to treatment failure in cancer (4), the evaluation of new treatment combinations 
which reinstate apoptosis competency has the potential to improve patient outcome. 
Novel targeted drugs which neutralize apoptosis-inhibiting proteins have potential as 
enhancers of chemotherapy responsiveness in cancer. The group of intracellular anti-
apoptotic proteins is relatively small, with caspase-8/-10 inhibitor FLIP, anti-apoptotic Bcl-2 
family members and inhibitor of apoptosis (IAP) proteins being the major players. The Bcl-2 
antagonist venetoclax/ABT-199 has recently been approved for the treatment of patients with 
17p deleted chronic lymphocytic leukemia and is currently being tested in additional cancers 
(5). From the group of IAP antagonists that have been evaluated, clinical studies have shown 
that TL32711/Birinapant (Tetralogics) and LCL161 (Novartis) can be combined safely with a 
range of chemotherapeutic agents, and both have entered phase 2 trials 
(http://clinicaltrials.gov/) (6). TL32711 generated responses in combination with irinotecan in 
a subset of colorectal cancer patients who were refractory to irinotecan alone (7). Such 
response heterogeneities indicate that stratification tools and response predictors will be 
required to preselect patients likely to respond to IAP antagonist-based combination treatments. 
IAP antagonists were initially designed to replicate the function of second mitochondria-
derived activator of caspases (SMAC) in binding to and blocking X-linked inhibitor of 
apoptosis protein (XIAP), the major antagonist of proteases essential for efficient apoptosis 
execution (caspases-9, -3 and -7) (8). IAP antagonists also bind to and trigger the rapid 
degradation of cellular IAP (cIAP) 1 and 2 (9), both of which are critical regulators of 
ripoptosome formation and caspase-8-dependent apoptosis induction in response to intrinsic 
pro-apoptotic stress and activation of tumour necrosis factor receptor (TNFR) family (6,8). 
Correspondingly, IAPs have been implicated as mediators of drug resistance in various 
cancers, including colorectal cancer (10,11).  
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In this study, we obtained a single cell understanding of signal transduction kinetics and 
heterogeneities for treatments based on combinations of 5-FU/oxaliplatin and TL32711, and 
applied a systems biology strategy towards predicting the resulting cell death patterns in 
populations of colon cancer cells in vitro and in vivo.  
 
Results 
IAP antagonist TL32711/Birinapant sensitizes CRC cell lines to chemotherapy-induced 
cell death. 
XIAP is implicated as an important mediator of clinical drug resistance (12). We assessed the 
role of XIAP in regulating the apoptotic response of colon cancer cells to the widely used 
therapeutic combination of 5-FU and oxaliplatin. Genetic loss of XIAP sensitized HCT116 
cells to cell death induced by 5-FU/oxaliplatin after 48h of treatment (Fig.1A). The cell death 
induced by 5-FU/oxaliplatin was caspase-dependent (implying apoptosis) since the pan-
caspase inhibitor zVAD-fmk abolished cell death in both parental and XIAP null cells 
(Fig.1B). These results indicate that XIAP is an important mediator of resistance to 5-
FU/oxaliplatin. We therefore co-treated HCT116 cells with 5-FU and oxaliplatin alone and in 
combination in the presence or absence of the IAP antagonist TL32711 and determined cell 
death by flow cytometry. In agreement with results in XIAP null cells, cell death was 
significantly increased by addition of TL32711 (Fig.1C). Similar results were obtained in the 
LoVo colon cancer model, with TL32711 enhancing apoptosis induced by 5-FU, oxaliplatin 
and the combination treatment (Fig.1D). In both cell lines, TL32711 alone had a relatively 
modest effect on cell death (~ 10% above background levels). 
 
IAP antagonist TL32711 promotes cIAP1 and cIAP2 depletion, formation of complex II 
and caspase-8/RIPK1-dependent cell death. 
We next further characterised the consequences of and the molecular signalling events 
initiated by TL32711 treatment. In both HCT116 and LoVo cells, TL32711 caused the rapid 
and persistent down-regulation of cIAP1 (Fig.2A). In many cell lines, cIAP2 expression 
recovers after initial rapid degradation induced by IAP antagonists; this is because cIAP1 acts 
as an E3 ligase for cIAP2, and degradation of cIAP1/2 leads to activation of the non-
canonical NFB pathway resulting in increased expression of NFB-driven genes, including 
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BIRC3, the gene encoding cIAP2 (13,14). It was therefore notable that cIAP2 expression was 
also persistently down-regulated in both cell line models in response to TL32711. While it is 
known that TL32711 also inhibits XIAP (Kd=45 nM) (15), the most potent caspase-inhibiting 
IAP that directly targets caspases-3, -7 and -9, XIAP expression was relatively unaffected by 
TL32711 in both cell lines (Fig.2A); this is consistent with the predominant effect of IAP 
antagonists on XIAP being disruption of its protein-protein interactions with caspases. In 
further dose-effect studies, we found that nanomolar concentrations of TL32711 were 
sufficient to cause the degradation of cIAP1 and cIAP2 in both cell lines (Fig.2B).  
The loss of cIAPs is known to promote the interaction of procaspase-8 with RIPK1, 
triggering the formation of complex II or the ripoptosome, a cytosolic caspase-8 activation 
platform that can trigger apoptosis. Genotoxic stress may also promote ripoptosome 
formation (16). Assessment of ripoptosome formation indicated that treatment with TL32711 
in combination with 5-FU increased RIPK1/procaspase-8 complex formation compared to 
treatment with TL32711 alone, and this was further enhanced when TL32711 was combined 
with 5-FU/oxaliplatin (Fig.2C), suggesting that standard-of-care chemotherapy promotes 
ripoptosome formation in colon cancer cells in the context of IAP antagonist treatment 
(Fig.2C). Importantly, this interaction was not observed when cells where exposed only to 
the chemotherapeutics (Fig.2C), indicating that TL32711 initiates an additional pro-apoptotic 
signalling cascade in parallel to other genotoxic responses in these cells. 
Next, we investigated whether the formation of procaspase-8/RIPK1 complexes also results 
in the activation of caspase-8. To specifically determine initiator caspase-8 activity inside 
living HCT116 cells, we measured the cleavage of an exogenously expressed CFP-YFP 
fusion protein containing the preferred caspase-8 cleavage motif IETD by FRET flow 
cytometry (17,18). To avoid contributions of downstream effector caspases-3 and -7, which 
both also cleave after IETD motifs, we conducted these experiments in HCT116 cells 
deficient in Bax and Bak (19). As shown in Fig.2D, only treatments including TL32711 
resulted in IETD probe cleavage in HCT116 cells. Furthermore, IETDase activity was 
completely eliminated when these cells were transfected with an siRNA targeting procaspase-
8 (Fig.2D). We next determined whether caspase-8 activation would be required to trigger 
MOMP. Indeed, depletion of procaspase-8 expression abolished mitochondrial depolarisation 
in parental HCT116 cells, specifically in response to TL32711/chemotherapy combination 
treatments (Fig.2E). To complement these analyses, we also depleted RIPK1 expression by 
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siRNA and determined cell death by flow cytometry; notably, loss of RIPK1 expression also 
significantly reduced cell death in TL32711 combination treatments (Fig.2F). 
Taken together, these findings demonstrate that the presence of TL32711 promotes the 
formation of complexes, presumably ripoptosomes, containing caspase-8 and RIPK1, 
resulting in upstream caspase-8 activation in a significant proportion of cells. In agreement 
with this, cell death co-depends on the presence of both procaspase-8 and RIPK1. 
 
Single-cell real-time imaging identifies two distinct caspase activation patterns leading to 
apoptosis execution in TL32711-based combination treatments. 
Next, we analysed the kinetics of intracellular apoptosis signal transduction in HCT116 and 
LoVo cells that responded to 5-FU/oxaliplatin and TL32711, alone or in combination. To this 
end, we expressed another CFP-YFP FRET probe, containing a DEVD linker motif 
preferentially cleaved by caspases-3/-7, but also cleavable by caspase-8 in HCT116 and 
LoVo cells (20). Readings obtained from this probe (cleavage amounts and kinetics) are also 
suitable to validate predictions made by deterministic mathematical modelling of apoptosis 
signalling as to whether apoptosis can be executed efficiently in human cancer cells, 
including CRC cell lines (21,22). Data obtained from these time-lapse imaging studies, in 
combination with the results from the previous experimental characterisations, also provided 
a basis for the subsequent development of an extended mathematical framework for 
simulating the responsiveness of colon cancer cell populations to treatment combinations that 
include the IAP antagonist TL32711. 
Cells stably expressing the FRET probe were treated and monitored over time by 
fluorescence microscopy, followed by ratiometric analysis of probe cleavage. As expected, 
individual cells responded with probe cleavage at different times after treatment (Fig.3A). In 
parallel, cells were loaded with TMRM to obtain data on mitochondrial transmembrane 
potentials, which depolarise upon MOMP and release of cytochrome c and can serve as a 
surrogate marker for timing the beginning of the apoptosis execution phase (21,23). For 
individual cells, fluorescence signals were extracted and plotted to obtain quantitative data on 
probe cleavage kinetics.  
In our measurements, we could observe two prominent response patterns of FRET probe 
cleavage in single cells (Fig.3B). In HCT116 cells, treatment with the chemotherapy 
combination of 5-FU/oxaliplatin resulted in classical post-MOMP patterns of FRET probe 
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cleavage during apoptosis execution (Fig.3Bi). Only a few cells responded to TL32711, and 
these presented with an initial phase of slow, modest probe cleavage (Fig.3Bii). This “ramp” 
of substrate cleavage was followed by a transition towards rapid probe cleavage once the 
execution phase was triggered (Fig.3Bii). These patterns were reminiscent of cleavage 
kinetics previously described by us and others for caspase-8-dependent apoptosis initiation 
(17,24). Upon combination of chemotherapeutics with TL32711, these dual-phase cleavage 
patterns were also observed (Fig.3Biii) and became more frequent. Nevertheless, a fraction of 
cells also responded with patterns comparable to chemotherapy-only treatments. Control cells 
which remained untreated did not display probe cleavage or significant changes in the FRET 
signal, excluding the possibility that phototoxicity or probe bleaching contributed to the 
signals recorded (not shown). Similar findings were also made in LoVo cells (Fig.3Bi-iii) 
An overall quantification of all responses is shown in Fig.3C,D. In particular, we determined 
the onset time of probe cleavage ramps as well as the slope of these ramps, serving as an 
indicator for pre-MOMP caspase-8 activity. In addition, we determined the mitochondrial 
MOMP threshold (amount of substrate cleaved at MOMP) as well as the onset time of the 
post-MOMP execution phase (Fig.3C,D). Overall, this demonstrated that moderate probe 
cleavage (“pre-MOMP ramp”), most likely due to caspase-8 activation (see Fig.2), in 
HCT116 can primarily be observed in the presence of TL32711 (Fig.3Ci). In the LoVo 
model, cells with pre-MOMP substrate cleavage could also be found in response to 5-
FU/oxaliplatin, and the fraction of these cells increased when TL32711 was combined with 5-
FU/oxaliplatin (Fig.3Di). We therefore conclude that response patterns within colon cancer 
cell populations are heterogeneous, with cells either displaying rapid FRET probe cleavage as 
expected for apoptosis execution, or initial moderate pre-MOMP caspase-8 activity, which 
subsequently is converted into rapid apoptosis execution. 
 
Mathematical simulations of apoptosis signalling can recapitulate death profiles and 
apoptosis sensitization by IAP antagonist TL32711. 
Next, we established a mathematical modelling framework that can replicate the apoptosis 
heterogeneity observed in HCT116 and LoVo cell populations. To this end, we extended a 
previous deterministic ODE-based model of the apoptosis execution phase that captures the 
interplay of the apoptosome (cytochrome c-induced APAF-1 oligomerisation and caspase-9 
activation), SMAC, XIAP and caspase-3 (21). The terminal outputs of this model are 
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simulated cleavage kinetics for DEVD caspase substrates, allowing the comparison of model 
outputs to time-lapse imaging data. Furthermore, we previously showed that >25% substrate 
cleavage during apoptosis execution is highly indicative of irreversible cell death induction 
(21). For the model extension here, we included a function which replicates pre-MOMP 
caspase-8 activity and also implemented a threshold mechanism by which prolonged caspase-
8 activity triggers apoptosis execution (see Fig.4A and methods). Importantly, we developed 
this model so that it can capture the cell-to-cell heterogeneity observed experimentally in 
HCT116 and LoVo cell populations. This was achieved by parameterising in silico ensembles 
of 1,000 cells for each treatment condition, where for each individual cell the respective 
initial model parameters were sampled from the distributions of experimental input data. To 
parameterise the reactant amounts, we determined the nM protein expression of key apoptosis 
regulators in HCT116 and LoVo cells by quantitative Western blotting (12-bit dynamic 
range) (Fig.4B). For the model, these quantities were converted to normal distributions 
around the measured mean (Fig.4C). Similarly, pre-MOMP signalling was parameterised 
with the experimentally determined heterogeneity data, including the frequency of upstream 
caspase-8 activation, onset times, activities and MOMP thresholds (see results in Figs.2, 3). 
In the subsequent simulations for HCT116 cell populations, we noted that chemotherapy or 
TL32711 on their own induced apoptosis execution in rather few cells of the simulated 
ensembles (Fig.4D). Calculating substrate cleavage and apoptosis execution for the 
combination of chemotherapy and TL32711 instead showed, as expected, that significantly 
more cells responded (Fig.4D). Similar simulation results were obtained for LoVo cells, with 
the combination of chemotherapy and TL32711 again resulting in significantly enhanced 
apoptosis execution (Fig.4E). These results therefore demonstrate that mathematical 
modelling can recapitulate apoptosis responses, the sensitizing effects of TL32711 and cell-
to-cell response heterogeneities observed experimentally in populations of colon cancer cells. 
 
Mathematical modelling predicts increased apoptosis resistance of xenografted HCT116 
and LoVo cell tumours, which can be overcome by chemotherapy/TL32711 co-treatment.  
Next, we assessed whether our mathematical modelling approach would allow us to calculate 
in vivo apoptosis sensitivity and effects on tumour growth in response 5-FU/oxaliplatin and 
TL32711. To this end, we established xenograft tumour growth models for HCT116 and 
LoVo cells. Since protein expression amounts in HCT116 and LoVo cells may differ between 
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in vitro and in vivo growth conditions, we first collected tumours grown in untreated control 
mice for protein quantification. Interestingly, we noted significant differences in apoptosis 
protein expression amounts between the two growth conditions in both HCT116 and LoVo 
cells (Fig.5A-C). In HCT116 cells, notable decreases in SMAC (1.7-fold), APAF-1 (4.7-fold) 
and Procaspase-9 (2.1-fold) expression were detected, whereas XIAP expression increased 
(3.4-fold) (Fig.5A-C). We made similar findings in tumours grown from LoVo cells, where 
again decreases in APAF-1 (3.8-fold) and procaspase-9 (2.7-fold) expression and increases in 
XIAP (2.1-fold) expression were observed, while procaspase-3 expression also decreased 
(1.7-fold) in these tumours (Fig.5A-C). We therefore used the in vivo protein expression data 
to re-parameterise our model and to calculate whether apoptosis responsiveness of HCT116 
and LoVo cell ensembles would be affected. Results from these simulations suggested that 
for in vivo conditions, poor responsiveness to both chemotherapy and TL32711 would be 
expected, indicating that the changes in protein expression observed in xenograft tumours 
impair apoptosis execution in a significant fraction of the populations (Fig.5D,E, compare to 
Fig.4D,E). The expected in vivo heterogeneity in execution efficacy is more explicitly shown 
in Supplemental Figure 1 (Fig.S1). Despite the strong trend towards higher apoptosis 
resistance, the simulation results also show that the combination of chemotherapy plus 
TL32711 would notably enhance cell death responses in HCT116 and LoVo xenografts 
(Fig.5D,E; Fig.S1). 
 
Mathematical modelling captures drug effects observed in vivo and predicts treatment 
responses. 
Cell death events accumulated from the cell ensemble simulations (Fig.5D,E) indicated that 
under in vivo conditions, the response of HCT116 and LoVo xenografts to chemotherapy and 
TL32711 combinations is considerably higher than for single treatment (Fig.6A,B). To 
validate the model predictions, we next treated mice growing HCT116 and LoVo cell 
tumours with 5-FU/oxaliplatin, TL32711 or the combination of both. As mathematically 
predicted for the in vivo setting, for both cell line models we indeed found significantly 
improved responses upon subjecting mice to the combination treatment with 5-FU/oxaliplatin 
and TL32711 compared to either 5-FU/oxaliplatin or TL32711 alone (Fig.6C). cIAP1 
expression was lost and cIAP2 expression decreased in tumour samples following TL32711-
based treatments, confirming that the IAP antagonist was efficacious in vivo. (Fig.6D). 
Interestingly, we found that cIAP2 expression was downregulated in both xenograft models 
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following 5-FU/oxaliplatin treatment; however, co-treatment with TL32711 partially restored 
cIAP2 levels, potentially due to activation of non-canonical NFB signalling following 
TL32711 treatment (8). Most notably, expression of XIAP was reduced in both xenograft 
models following co-treatment with 5-FU/oxaliplatin and TL32711 (Fig.6D).  
 
Next, we examined how well the effects of the different treatments on reducing in vivo 
tumour growth would correlate with the treatment-specific predictions obtained from the 
mathematical model. We first determined the effects of the different treatments on tumour 
volume changes over time. To this end, we replicated experimentally measured tumour 
volume changes of individual mice by a growth impairment model, incorporating factors that 
represented maximal asymptotic growth and proliferation rates. From this, we obtained the 
respective drug effects (KD) that contribute to the observed growth impairment (25,26) (see 
also methods). The tumour volume changes could be fitted by the growth model, as seen by 
comparing pooled fitting data on volume changes to experimental data (Fig.6E,F; Fig.6C). 
When plotting cell death predictions against the drug effects obtained from the 
experimentally observed tumour volume changes (Fig.6G), we found that the model 
predictions indeed correlated strongly with the observed in vivo treatment responses. These 
results therefore confirmed that our mathematical model can predict in vivo responses of 
different CRC cell lines to standard of care chemotherapy, IAP antagonist TL32711 and the 
combination of both.  
 
 
Discussion 
Colorectal cancer is the 2nd leading cause of cancer-related death in the Western world. In 
stage IV metastatic disease, median overall survival (OS) is only 21-24 months, 5 year OS 
rates are <6% and 10 year OS rates <1% (27). IAP antagonists have been demonstrated to 
synergise with numerous anti-cancer drugs in various model systems (6), and several IAP 
antagonists are currently in phase II clinical trials (http://clinicaltrials.gov/). TL32711 is in 
clinical trials for the treatment of several advanced solid tumours, haematological 
malignancies and chronic hepatitis B and has been combined with the apoptosis-inducing 
human monoclonal antibody conatumumab in patients with relapsed epithelial ovarian cancer 
(NCT01940172). In a phase II clinical trial combining TL32711 and irinotecan in colorectal 
cancer patients refractory to irinotecan, the combination was tolerated similar to irinotecan 
11 
 
alone resulted in clinical benefits particularly in patients with mutated KRAS 
(NCT01188499). However, patient selection strategies for IAP antagonists both as 
monotherapies and in combination with other agents are currently lacking. 
Having found that XIAP impairs chemotherapy-induced cell death in CRC cells, we 
mechanistically and quantitatively characterised the impact of the IAP antagonist TL32711 
on chemotherapy-induced cell death in vitro and in vivo, taking into account cell-to-cell 
heterogeneity in isogenic cell populations. Subsequently, we developed a systems biology-
based approach towards predicting treatment responsiveness to single and combination 
treatments of TL32711 with standard-of-care CRC chemotherapy in such cell populations. 
Results from the mathematical simulations correlated robustly with the observed drug effects 
on xenograft tumour growth in mice.  
IAP antagonist-dependent degradation of cIAPs can induce intrinsic ripoptosome formation 
(30,31), a finding we could confirm in CRC cells treated with TL32711. Interestingly, in 
contrast to work in fibrosarcoma, breast adenocarcinoma, rhabdomyosarcoma or ovarian 
carcinoma cell lines (16), chemotherapy alone was not sufficient to induce ripoptosome 
formation in CRC cells, but significantly enhanced the limited ripoptosome formation 
observed after TL32711 monotherapy. Consequently, depletion of procaspase-8 or RIPK1 
abrogated cell death induced by TL32711/chemotherapy combinations. Our imaging data 
reveal that in response to TL32711/chemotherapy co-treatment, genetically identical cells 
differ in their mode of cell death induction, with both pre-MOMP caspase activation being 
observed (most likely due to ripoptosome formation), as well as subpopulations which trigger 
MOMP without prior caspase activation. We currently cannot answer where these response 
heterogeneities emerge from, but speculate that stochastic cell-to-cell heterogeneities in 
baseline protein expression might be sufficient for these differences. In addition, cell cycle 
asynchronies might contribute, since a number of apoptosis-regulating proteins are known to 
be cell cycle regulated and since cells in different phases of the cell cycle will encounter 
different cell cycle checkpoints upon chemotherapy-induced DNA damage (32). The existing 
uncertainties regarding these crucial upstream signalling processes as well as the currently 
limited quantitative and kinetic knowledge of ripoptosome formation are the reasons why in 
our mathematical model, the upstream signalling was modelled from the behaviour of cell 
populations. 
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Of note, it has been reported that certain cell lines might secrete TNF- and die by autocrine 
TNFR1-dependent complex II formation and caspase-8 activation. In our studies, neither 
HCT116 nor LoVo cells secreted TNF- in response to TL32711 (not shown). However, we 
cannot exclude that the presence of TNF- in tumour microenvironments further contributes 
to treatment efficacy. Indirect evidence for this might emerge in the field of melanoma 
therapies, where it was recently described that the combination of TL32711 and 
chemotherapy does not induce response synergies in vitro, although single-treatment with 
TL32711 significantly impaired in vivo xenograft growth (33,34). While our systems model 
already captures in vivo drug effects with very promising accuracy for single and 
combination treatments of TL32711 and CRC chemotherapy, the future inclusion of 
microenvironmental TNF- signalling might further improve the performance.  
We believe that our approach of using mathematical simulations to predict in vivo efficacy of 
novel apoptosis-targeted agents such as IAP antagonists might have potential for contributing 
to the future personalisation and optimisation of treatments. We recently demonstrated the 
added value of mathematically modelling apoptosis competency in combination with clinic-
pathological markers for prognosticating disease outcome in chemotherapy-treated stage III 
CRC patients (35); in the future, similar approaches could be followed for chemotherapy/IAP 
antagonist combination therapies. Moreover, this basic framework could be extended to take 
account of the influence of tumour architectures, vascularisation, microenvironmental 
heterogeneities as well as whole body drug PK/PD (36,37). More advanced experimental 
models, such as patient-derived xenografts, would provide ideal testing grounds for such 
model extension, refinement and optimisation.  
In summary, this work provides proof-of-principle and in the future could possibly provide 
the basis for contributing to development of clinical tests in identifying colorectal cancer 
patients who are most likely to benefit from the addition of IAP antagonists to standard-of-
care chemotherapeutics.  
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Materials and Methods   
Compounds and plasmids 
TL32711 was obtained from Active Biochem (Maplewood, NJ). 5-FU (Medac) and 
oxaliplatin (Accord) were obtained from Belfast City Hospital. z-VAD-fmk was purchased 
from Merck Millipore (Darmstadt, Germany). Plasmids for the expression of the CFP-YFP 
FRET probes were described previously (17,20). 
Cell lines 
HCT116 and LoVo cell lines were purchased as authenticated stocks from ATCC 
(Teddington, UK). HCT116 XIAP-/0 cells were provided by Dr B. Vogelstein (Johns Hopkins 
University). HCT116 (Bax/Bak)-/- cells were kindly provided by Dr R.J. Youle (National 
Institute of Neurological Disorders and Stroke). 
siRNA Transfections 
Scrambled control and RIPK1 siRNA (ON-TARGET SMART pool) were obtained from 
Dharmacon (Chicago, IL). Caspase-8 siRNA (5’GAGUCUGUGCCCAAAUCAATT3’) was 
purchased from Qiagen (Crawley, UK). siRNA transfections were carried out with 
Lipofectamine RNAiMAX transfection reagent (Invitrogen, Paisley, UK) according to 
manufacturer’s instructions. 
Western blotting 
Western blotting was carried out as previously described (21). cIAP1, cIAP2 and caspase-8 
antibodies were from Enzo (Exeter, UK). XIAP, caspase-3, SMAC, APAF-1, caspase-9 and 
cytochrome c antibodies were from Cell Signaling Technology (Danvers, MA). β-actin 
antibody was from Sigma (Missouri) and FLIP antibody from AdipoGen (San Diego, CA). 
Secondary antibodies were purchased from LI-COR Biosciences (Lincoln, NE). Images were 
captured using an Odyssey Imaging System (LICOR, Lincoln, NE) at 12 bit dynamic range. 
Quantification of protein expression amounts was conducted as described previously (21). 
Immunoprecipitation 
Cells were pre-treated with 10 μM z-VAD-fmk for 1 h prior to treatment with 
chemotherapy/TNFα/TL32711 combinations. Cells were lysed in CHAPS buffer (30 mM 
Tris pH7.5, 150 mM NaCl, 1% CHAPS). 1 μg of caspase-8 p18 or IgG isotype control 
antibody (Santa Cruz, CA) was conjugated with 25 μL ProteinG Dynabeads (Invitrogen, 
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Paisley, UK). Protein lysate (750 μg) was immunoprecipitated for 6 h at 4°C. Ripoptosome 
formation was analysed by Western blotting for RIPK1 (BD Transduction Laboratories). 
Flow cytometry  
Apoptosis induction was determined by Annexin V/propidium iodide analysis. Cells were 
harvested and stained according to the manufacturer’s instructions (BD Biosciences, Oxford, 
UK). For measurements of mitochondrial membrane potentials, cells were incubated with 25 
nM tetra-methyl-rhodamine ethyl ester (TMRE; Sigma, Missouri) for 15 minutes at 37°C. 
Cells were then trypsinized, washed in PBS and analyzed immediately. For FRET-based 
measurements of caspase-8 activation, Bax/Bak deficient HCT116 cells stably expressing the 
IETD FRET probe were generated and analyzed as described before (18).  
Time lapse imaging and FRET analysis  
Imaging settings and image analysis workflows for FRET disruption kinetics and for the 
timing of mitochondrial depolarisation at the single-cell level were described previously 
(17,38). All measurements were performed using stably transfected and clonally expanded 
cells. Cells were not synchronised prior to analysis to avoid potential cell cycle-dependent 
bias. Treatment durations exceeded two cell cycle durations to obtain authentic data from 
otherwise unperturbed cell populations. 
Xenograft Experiments 
Female BALB/c nude mice were maintained as previously described (39). All procedures 
were carried out in accordance with the Animals (Scientific Procedures) Act, 1986 under 
project licence (PPL 2590b). Mice were implanted in each flank with 2x106 HCT116 or 
2.5x106 LoVo cells in Matrigel (BD, Oxford, UK). Upon establishment of ~100 mm3 
tumours (HCT116, day 5; LoVo, day 11), mice were randomised to treatment groups. Groups 
were treated with vehicle, 5-FU/oxaliplatin, TL32711, or 5-FU/oxaliplatin in combination 
with TL32711. All treatments were administered by IP injection. TL32711 powder was 
reconstituted in 1% DMSO/Peanut oil (Sigma, Missouri), and mice were injected with 30 
mg/kg three times per week. 5-FU was administered at 15 mg/kg in PBS (Gibco) on a 5 day 
on/2 day off schedule. Oxaliplatin was administered at 2 mg/kg in H2O once a week. Tumour 
volume was assessed through measuring two dimensions using digital callipers three times 
per week. Two xenografts were collected per cell line from control mice to determine in vivo 
protein expression amounts.  
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Mathematical modelling 
MATLAB including Statistics Toolbox Release 2014b (The MathWorks., Cambridge, UK) 
was used for mathematically modelling apoptosis signalling in response to chemotherapy, 
TL32711 or the combination of both. For processes subsequent to MOMP, we employed 
APOPTO-CELL, an ordinary differential equations-based model previously validated to 
reliably simulate apoptosis execution (21,40). This model provides kinetics of CFP-DEVD-
YFP FRET substrate cleavage as an output that can be compared to experiments in which 
such probes are used. To simulate the slow and modest substrate cleavage prior to MOMP 
(“pre-MOMP ramps”), the upstream signalling was modelled using a heuristic function that 
feeds into and triggers the execution phase model. The technical implementation is described 
in Supplemental Information SI1.  
Correlation of model predictions and drug effects on tumour growth  
Tumour growth inhibitory effects (ܭ஽) induced by the respective treatments were estimated 
from the in vivo tumour growth data. For this, we expressed the observed volume change 
over time (ௗ௏ௗ௧) from the difference between tumour growth when untreated and a treatment-
mediated reduction in growth (25,26). Model-predicted cell death and drug effects on in vivo 
tumour growth (ܭ஽ሻ were then tested for correlation (Pearson and Spearman). The technical 
implementation is described in Supplemental Information SI1. 
Statistics 
All statistical analyses were performed in Graphpad Prism (GraphPad Software, Inc, CA, 
USA). Data are shown as mean values ± s.d., unless otherwise indicated.  Two-tailed 
Student’s t tests were used for group comparisons. p values ≤ 0.05 were considered to be 
statistically significant. 
 
Conflict of interest: The authors declare no conflict of interest. 
Acknowledgements: The authors kindly acknowledge support for their work by grants from 
the European Union (FP7 APO-DECIDE) and Science Foundation Ireland/Department for 
Employment and Learning Northern Ireland Investigator Programme (14/IA/2582; 
13/IA/1881). CTH and FAL received support from the Irish Research Council 
(GOIPD/2013/102; GOIPG/2014/1299). MR receives further support from the German 
Research Foundation (FOR2036, MO 3226/1-1).  
16 
 
References  
1. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., 
Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., 
Hendler, D., de Braud, F., Wilson, C., Morvan, F., and Bonetti, A. (2000) Leucovorin and 
fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J 
Clin Oncol 18, 2938-2947 
2. De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F., and Tejpar, S. (2011) KRAS, 
BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic 
colorectal cancer. Lancet Oncol 12, 594-603 
3. Hurwitz, H. I., Tebbutt, N. C., Kabbinavar, F., Giantonio, B. J., Guan, Z. Z., Mitchell, L., 
Waterkamp, D., and Tabernero, J. (2013) Efficacy and safety of bevacizumab in metastatic 
colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18, 
1004-1012 
4. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 
646-674 
5. Delbridge, A. R., Grabow, S., Strasser, A., and Vaux, D. L. (2016) Thirty years of BCL-2: 
translating cell death discoveries into novel cancer therapies. Nat Rev Cancer 16, 99-109 
6. Fulda, S. (2015) Promises and Challenges of Smac Mimetics as Cancer Therapeutics. Clin 
Cancer Res 21, 5030-5036 
7. Senzer, N. N., LoRusso, P., Martin, L. P., Schilder, R. J., Amaravadi, R. K., Papadopoulos, K. 
P., Segota, Z. E., Weng, D. E., Graham, M., and Adjei, A. A. (2013) Phase II clinical activity 
and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-
relapsed/refractory metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts) 31, 3621 
8. Fulda, S. (2014) Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from 
molecular mechanism to therapeutic application. Clin Cancer Res 20, 289-295 
9. Gyrd-Hansen, M., and Meier, P. (2010) IAPs: from caspase inhibitors to modulators of NF-
kappaB, inflammation and cancer. Nat Rev Cancer 10, 561-574 
10. Hector, S., and Prehn, J. H. (2009) Apoptosis signaling proteins as prognostic biomarkers in 
colorectal cancer: a review. Biochim Biophys Acta 1795, 117-129 
11. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., 
Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. (2000) Expression and 
prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin 
Cancer Res 6, 1796-1803 
12. Obexer, P., and Ausserlechner, M. J. (2014) X-linked inhibitor of apoptosis protein - a critical 
death resistance regulator and therapeutic target for personalized cancer therapy. Frontiers in 
oncology 4, 197 
13. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, 
P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., 
Deshayes, K., Dixit, V. M., and Vucic, D. (2007) IAP antagonists induce autoubiquitination 
of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681 
14. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., 
Chunduru, S. K., Condon, S. M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., 
Schneider, P., Callus, B. A., Koentgen, F., Vaux, D. L., and Silke, J. (2007) IAP antagonists 
target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693 
15. Allensworth, J. L., Sauer, S. J., Lyerly, H. K., Morse, M. A., and Devi, G. R. (2013) Smac 
mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast 
cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res 
Treat 137, 359-371 
16. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., 
Lopez, J., MacFarlane, M., Cain, K., and Meier, P. (2011) The Ripoptosome, a signaling 
platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43, 432-
448 
17 
 
17. Hellwig, C. T., Kohler, B. F., Lehtivarjo, A. K., Dussmann, H., Courtney, M. J., Prehn, J. H., 
and Rehm, M. (2008) Real time analysis of tumor necrosis factor-related apoptosis-inducing 
ligand/cycloheximide-induced caspase activities during apoptosis initiation. J Biol Chem 283, 
21676-21685 
18. Laussmann, M. A., Passante, E., Dussmann, H., Rauen, J. A., Wurstle, M. L., Delgado, M. E., 
Devocelle, M., Prehn, J. H., and Rehm, M. (2011) Proteasome inhibition can induce an 
autophagy-dependent apical activation of caspase-8. Cell Death Differ 18, 1584-1597 
19. Wang, C., and Youle, R. J. (2012) Predominant requirement of Bax for apoptosis in HCT116 
cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 31, 3177-3189 
20. Rehm, M., Dussmann, H., Janicke, R. U., Tavare, J. M., Kogel, D., and Prehn, J. H. (2002) 
Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase 
activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 277, 24506-
24514 
21. Rehm, M., Huber, H. J., Dussmann, H., and Prehn, J. H. (2006) Systems analysis of effector 
caspase activation and its control by X-linked inhibitor of apoptosis protein. The EMBO 
journal 25, 4338-4349 
22. Schmid, J., Dussmann, H., Boukes, G. J., Flanagan, L., Lindner, A. U., O'Connor, C. L., 
Rehm, M., Prehn, J. H., and Huber, H. J. (2012) Systems Analysis of Cancer Cell 
Heterogeneity in Caspase-dependent Apoptosis Subsequent to Mitochondrial Outer 
Membrane Permeabilization. J Biol Chem 287, 41546-41559 
23. Dussmann, H., Rehm, M., Kogel, D., and Prehn, J. H. (2003) Outer mitochondrial membrane 
permeabilization during apoptosis triggers caspase-independent mitochondrial and caspase-
dependent plasma membrane potential depolarization: a single-cell analysis. J Cell Sci 116, 
525-536. 
24. Albeck, J. G., Burke, J. M., Aldridge, B. B., Zhang, M., Lauffenburger, D. A., and Sorger, P. 
K. (2008) Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. 
Mol Cell 30, 11-25 
25. Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J. M., Hlatky, L., and Hahnfeldt, P. 
(2014) Classical mathematical models for description and prediction of experimental tumor 
growth. PLoS Comput Biol 10, e1003800 
26. Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., Pesenti, E., Germani, M., 
Poggesi, I., and Rocchetti, M. (2004) Predictive pharmacokinetic-pharmacodynamic 
modeling of tumor growth kinetics in xenograft models after administration of anticancer 
agents. Cancer Res 64, 1094-1101 
27. Van Schaeybroeck, S., Allen, W. L., Turkington, R. C., and Johnston, P. G. (2011) 
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin 
Oncol 8, 222-232 
28. Mitsuuchi, Y., Benetatos, C. A., Deng, Y., Haimowitz, T., Beck, S. C., Arnone, M. R., 
Kapoor, G. S., Seipel, M. E., Chunduru, S. K., McKinlay, M. A., Begley, C. G., and Condon, 
S. M. (2017) Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-
mediated NF-kappaB signaling by degrading TRAF2-associated cIAP1 in cancer cells. Cell 
death discovery 3, 16046 
29. Sun, H., Nikolovska-Coleska, Z., Lu, J., Meagher, J. L., Yang, C. Y., Qiu, S., Tomita, Y., 
Ueda, Y., Jiang, S., Krajewski, K., Roller, P. P., Stuckey, J. A., and Wang, S. (2007) Design, 
synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac 
mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Journal of the 
American Chemical Society 129, 15279-15294 
30. Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., 
Macfarlane, M., Hacker, G., and Leverkus, M. (2011) cIAPs Block Ripoptosome Formation, 
a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by 
cFLIP Isoforms. Mol Cell  
31. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., 
Lopez, J., Macfarlane, M., Cain, K., and Meier, P. (2011) The Ripoptosome, a Signaling 
Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs. Mol Cell  
18 
 
32. Clarke, P. R., and Allan, L. A. (2009) Cell-cycle control in the face of damage--a matter of 
life or death. Trends in cell biology 19, 89-98 
33. Vetma, V., Rozanc, J., Charles, E. M., Hellwig, C. T., Alexopoulos, L. G., and Rehm, M. 
(2017) Examining the In-Vitro Efficacy of the IAP Antagonist Birinapant as a Single-Agent 
or in Combination with Dacarbazine to Induce Melanoma Cell Death. Oncology research  
34. Krepler, C., Chunduru, S. K., Halloran, M. B., He, X., Xiao, M., Vultur, A., Villanueva, J., 
Mitsuuchi, Y., Neiman, E. M., Benetatos, C., Nathanson, K. L., Amaravadi, R. K., 
Pehamberger, H., McKinlay, M., and Herlyn, M. (2013) The novel SMAC mimetic birinapant 
exhibits potent activity against human melanoma cells. Clin Cancer Res 19, 1784-1794 
35. Salvucci, M., Wurstle, M. L., Morgan, C., Curry, S., Cremona, M., Lindner, A. U., Bacon, O., 
Resler, A. J., Murphy, A. C., O'Byrne, R., Flanagan, L., Dasgupta, S., Rice, N., Pilati, C., 
Zink, E., Scholler, L. M., Toomey, S., Lawler, M., Johnston, P. G., Wilson, R., Camilleri-
Broet, S., Salto-Tellez, M., McNamara, D. A., Kay, E. W., Laurent-Puig, P., Van 
Schaeybroeck, S., Hennessy, B. T., Longley, D. B., Rehm, M., and Prehn, J. H. (2017) A 
Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal 
Cancer. Clin Cancer Res 23, 1200-1212 
36. Eissing, T., Kuepfer, L., Becker, C., Block, M., Coboeken, K., Gaub, T., Goerlitz, L., Jaeger, 
J., Loosen, R., Ludewig, B., Meyer, M., Niederalt, C., Sevestre, M., Siegmund, H. U., 
Solodenko, J., Thelen, K., Telle, U., Weiss, W., Wendl, T., Willmann, S., and Lippert, J. 
(2011) A computational systems biology software platform for multiscale modeling and 
simulation: integrating whole-body physiology, disease biology, and molecular reaction 
networks. Front Physiol 2, 4 
37. Altrock, P. M., Liu, L. L., and Michor, F. (2015) The mathematics of cancer: integrating 
quantitative models. Nat Rev Cancer 15, 730-745 
38. Rehm, M., Parsons, M. J., and Bouchier-Hayes, L. (2015) Measuring caspase activity by 
Forster resonance energy transfer. Cold Spring Harbor protocols 2015, pdb prot082560 
39. Wilson, T. R., McLaughlin, K. M., McEwan, M., Sakai, H., Rogers, K. M., Redmond, K. M., 
Johnston, P. G., and Longley, D. B. (2007) c-FLIP: a key regulator of colorectal cancer cell 
death. Cancer Res 67, 5754-5762 
40. Huber, H. J., Rehm, M., Plchut, M., Dussmann, H., and Prehn, J. H. (2007) APOPTO-CELL--
a simulation tool and interactive database for analyzing cellular susceptibility to apoptosis. 
Bioinformatics 23, 648-650 
 
 
  
19 
 
Figure Legends 
Figure 1: XIAP depletion and IAP antagonist TL32711 sensitize CRC cell lines to 
chemotherapy-induced cell death. (A) AnnexinV/PI staining of HCT116 and HCT116 xiap-/0 
cells treated with 5FU (10 µM) and oxaliplatin (2 µM) for up to 48 h. (B) AnnexinV/PI 
staining of HCT116 and HCT116 xiap-/0 cells treated with oxaliplatin and 5FU for up to 48 h 
in presence or absence of 20 µM pan-caspase inhibitor z-VAD-fmk. (C,D) Annexin V/PI 
staining of HCT116 and LoVo cells 48 h following single or combination treatment with 10 
μM 5FU, 2 μM oxaliplatin and 1 μM TL32711. All data are shown as mean +/- s.e.m. from n 
= 3 independent experiments. 
Figure 2: IAP antagonist TL32711 promotes cIAP1,2 depletion, formation of complex II 
and caspase-8/RIPK1-dependent cell death. (A) Western blot analysis of cIAP1, cIAP2 and 
XIAP expression in HCT116 and LoVo cells following treatment with 1 μM TL32711. β-
actin served as loading control. (B) Western blot analysis of cIAP1, cIAP2 and XIAP 24 h 
following treatment with varying concentrations of TL32711 in HCT116 and LoVo cells. β-
actin served as loading control. (C) Western blot analysis of RIPK1 and procaspase-8 
following caspase-8 immunoprecipitation 48 h following treatment with 10 μM 5FU, 2 μM 
oxaliplatin and 3 h after addition of 1 μM TL32711 in the presence of 10 μM z-VAD-fmk in 
HCT116 cells. Input controls demonstrate presence of RIPK1 and procaspase-8 in all lysates. 
(D) Caspase-8-like (IETDase) activity was measured in HCT116 (Bax/Bak)-/- cells 
expressing a CFP-IETD-YFP FRET probe and that were transfected with scrambled control 
(SCR) siRNA or siRNA targeting procaspase-8 (C8si). Data are shown as mean +/- s.d. from 
triplicates. Experiment was repeated twice with similar results. (E) Mitochondrial 
depolarisation as determined by loss of TMRE uptake in HCT116 cells transfected with 
scrambled control (SCR) siRNA or siRNA targeting procaspase-8 (C8si). Cells were (co-
)treated with 1 μM TL32711 (TL), 10 μM 5FU and 2 μM oxaliplatin (oxali) for 48 h.  
Western blot insert demonstrates efficient depletion of procaspase-8 (PC8) expression. (F) 
Annexin V/PI staining of HCT116 transfected with scramble control (SCR) siRNA or siRNA 
targeting RIPK1 and (co-)treated with 1 μM TL32711 (TL), 10 μM 5FU and 2 μM oxaliplatin 
(oxali) for 48 h. Western blot insert demonstrates efficient depletion of RIPK1 expression. *p 
< 0.05; **p < 0.01. 
Figure 3: Single-cell real-time imaging identifies two distinct caspase activation patterns 
leading to apoptosis execution in TL32711-based combination treatments. (A) Pseudo 
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coloured CFP/YFP emission ratio images of a group of HCT-116 cells expressing a 
DEVDase FRET probe treated with 5FU/oxaliplatin (10 µM/ 2 μM) in combination with 
TL32711 (1 μM). DEVDase activity resulted in FRET probe cleavage and displayed as an 
increase in the CFP/YFP emission ratio. Loss of TMRM fluorescence indicates mitochondrial 
depolarisation as a consequence of MOMP. Time stamps indicate time after stimulus 
addition. (B) Exemplary DEVDase response profiles of HCT116 cells (upper panels) treated 
with 5FU/oxaliplatin, TL32711 or the combination of both. Cells responding to 
5FU/oxaliplatin predominantly showed late DEVDase activity, subsequent to the onset of 
mitochondrial depolarisation and corresponding to the canonical activation of the intrinsic 
apoptosis pathway (i). Cells responding to TL32711 single treatment exclusively displayed 
response patterns resembling the one shown in (ii), with mild DEVDase activity converted 
into rapid substrate cleavage following onset of mitochondrial depolarisation. Cells treated 
with the combination of 5FU/oxaliplatin and TL32711 frequently presented substrate 
cleavage ramps prior to the onset of mitochondrial depolarisation (iii), as well as response 
patterns without pre-MOMP caspase activity, resembling those shown in (i). Similar response 
characteristics were observed in LoVo cells (i-iii). (C) Quantification of response types and 
kinetics. For all HCT116 and LoVo cells responding to the treatments, the response 
characteristics were analysed and quantified. Parameters evaluated included the onset time of 
pre-MOMP caspase activity (time from drug addition to initiator caspase activation), the 
slope of pre-MOMP substrate cleavage as a measure of caspase activity, the mitochondrial 
MOMP threshold (amount of substrate cleaved at the time MOMP-induced mitochondrial 
depolarisation begins), as well as the onset time of the execution phase. Data are shown 
median +/- quartiles.  
Figure 4: Mathematical simulations of apoptosis signalling can recapitulate death profiles 
and apoptosis sensitization by IAP antagonist TL32711. (A) Overview of the architecture of 
the developed model. Data from experimental analyses of signalling kinetics upstream of 
MOMP were used to construct mathematical functions replicating early signalling 
characteristics. These then feed into and trigger the execution phase of apoptosis. The 
execution phase was simulated using a validated model based on coupled ordinary 
differential equations. The primary model output reflecting cellular apoptosis competency is 
the calculated amount of cellular substrates cleaved by caspases. A substrate cleavage above 
25% is considered to be sufficient for successful apoptosis execution. The diagram insert 
shows exemplary cell behaviours, such as non-responsive cells and cells responding at 
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different times and with different SC thresholds for MOMP induction. See methods section 
for details. (B) Mean expression of key players of apoptosis execution as quantified in 
HCT116 and LoVo cells from n = 3 experiments using quantitative immunoblotting. (C) 
Cellular protein expression converted into normal distributions. Random sampling from these 
distributions served to parameterise the apoptosis execution module of the mathematical 
model. (D,E) The behaviour of ensembles of 1,000 cells per treatment condition was 
mathematically modelled for HCT116 cells (D) or LoVo cells (E). Cell ensembles were 
parameterised as described in the methods and results sections. Each line represents the 
behaviour of one cell in the modelled ensemble. Near-vertical lines indicate phases of rapid 
substrate cleavage as observed during apoptosis execution. Ramps represent phases of pre-
MOMP substrate cleavage. Modelling results replicate experimental findings: Cells 
heterogeneously respond with apoptosis induction and execution, with combination treatment 
of chemotherapy and TL32711 causing higher amounts of cell death.  
Figure 5: Systems modelling predicts increased apoptosis resistance of xenografted 
HCT116 and LoVo cell tumours, which can be overcome by chemotherapy/TL32711 co-
treatment. (A) Comparison of baseline protein expression between in vitro and in vivo (day 7 
after inoculation) growth conditions prior to treatment. For the in vivo setting, two xenografts 
were collected per cell line. Representative immunoblots from whole cell extracts of HCT116 
and LoVo cells are shown. (B, C) For each cell line, protein expression amounts (nM) were 
quantified (n = 3-4 detections) using quantitative immunoblotting. (D,E) The apoptosis 
competency of ensembles of 1,000 cells per treatment condition was mathematically 
modelled for HCT116 cells (D) or LoVo cells (E) for in vivo growth conditions.  
Figure 6: Mathematical modelling captures drug effects observed in vivo and predicts 
treatment responses. (A,B) Accumulated cell death as obtained from mathematically 
modelling apoptosis execution in HCT116 or LoVo cell ensembles at in vivo growth 
conditions. (C,D) Fold change in tumour volume in HCT116 and LoVo xenograft models in 
control, TL32711, 5FU and oxaliplatin and 5FU, oxaliplatin and TL32711 groups. 
Treatments of 15 mg/kg 5FU, 2 mg/kg oxaliplatin and 30 mg/kg TL32711 were administered 
by IP injection as indicated.  Error bars indicate s.e.m. (D) Western blot analysis of cIAP1, 
cIAP2 and XIAP expression in HCT116 and LoVo xenograft tumours before and after 
treatment. β-actin served as loading control. (E,F) Pooled results from fitted tumour growth 
curves obtained from individual tumours. Traces indicate mean volume changes over time; 
shaded areas indicate variance (25th – 75th percentile), obtained by bootstrapping, within the 
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treatment group. (G) Correlation analysis between simulated cell death and the drug effects 
(ܭ஽ሻ obtained from (E, F). Error bars indicate s.d., obtained from bootstrapping.  
Supplemental Figure 1: Mathematical simulations of in vitro and in vivo apoptosis 
competency subsequent to MOMP. (A-D) The behaviour of ensembles of 1,000 cells per 
treatment condition was mathematically modelled for HCT116 cells in vitro (A) and in vivo 
(B) or LoVo cells in vitro (C) and in vivo (D). Cell ensembles were parameterised as 
described in the main manuscript. Each line represents the behaviour of one cell in the 
modelled ensemble. High amounts of substrate cleavage indicate that modelled cells are 
capable of executing apoptosis efficiently. Absent substrate cleavage or low amounts of 
substrate cleavage indicate failure to efficiently execute apoptosis. The simulation results 
indicate that post-MOMP heterogeneity is particularly prominent at in vivo conditions.  
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Supplemental Information I 
 
Technical implementation of mathematical models and predictions on drug effects on tumour 
growth. 
 
Mathematical modelling 
We used MATLAB equipped with the Statistics, Parallel Computing, and Optimization toolboxes 
(MATLAB, release 2014b, The MathWorks, Inc., Cambridge, UK) to build a mathematical model that 
simulates apoptosis signal transduction in response to chemotherapy, TL32711 or the combination of 
both in cell populations. To model the processes subsequent to mitochondrial outer membrane 
permeabilisation (MOMP) we employed APOPTO-CELL, an ordinary differential equations (ODE)-
based model previously validated to reliably simulate signal transduction during the apoptosis 
execution phase (1, 2), as a module of the overall modelling framework. This model provides the 
kinetics of CFP-DEVD-YFP FRET substrate cleavage as an output, providing the possibility for 
comparison to experiments in which such probes are used. To simulate the slow and modest substrate 
cleavage prior to MOMP (“pre-MOMP ramps”), the upstream signalling was modelled using a 
heuristic function which feeds into and triggers the execution phase ODE model. This function 
captures both the period where FRET substrate is not yet cleaved as well as the period of on-going 
pre-MOMP substrate cleavage. Combined with the APOPTO-CELL model of the apoptosis execution 
phase, FRET substrate cleavage (SC) over time can thereby be described in its entirety: 
 
ܵܥሺݐሻ ൌ
ۖە
۔
ۖۓ 0, ݐ௦௧௔௥௧	௧௥௘௔௧௠௘௡௧ ൑ ݐ ൏ ݐ௢௡௦௘௧	௣௥௘ିெைெ௉	௥௔௠௣∆ܵܥ
∆ݎܽ݉݌	ݐ݅݉݁ ݐ, ݐ௢௡௦௘௧	௣௥௘ିெைெ௉	௥௔௠௣ ൑ ݐ ൏ ݐ௢௡௦௘௧	௘௫௘௖௨௧௜௢௡	௣௛௔௦௘
ܣܱܱܲܲܶ െ ܥܧܮܮ൫ݐ, ܵܥ௢௡௦௘௧	௘௫௘௖௨௧௜௢௡	௣௛௔௦௘, ܶܮ32711, ࡼ൯, ݐ ൒ ݐ௢௡௦௘௧	௘௫௘௖௨௧௜௢௡	௣௛௔௦௘	
 
 
Here, ∆ௌ஼∆௥௔௠௣	௧௜௠௘ denotes the slope of pre-MOMP substrate cleavage and ܵܥ௢௡௦௘௧	௘௫௘௖௨௧௜௢௡	௣௛௔௦௘ the 
amount of substrate cleaved at the time the rapid execution phase is initiated, the latter being modelled 
by the default APOPTO-CELL module. The concentration of IAP-antagonists is accounted for by 
ܶܮ32711. The vector ࡼ comprises protein expression amounts for Procaspase-3, Procaspase-9, 
SMAC, XIAP and Apaf-1 as further model inputs. Ranges for response times, frequencies and 
cleavage rates required for model parameterisation were obtained from experimental data collected 
from HCT116 and LoVo cell ensembles treated with 5-FU/Oxaliplatin, TL32711 or 5-FU/Oxaliplatin 
+ TL32711. Protein expression ranges were obtained from quantitative analyses of HCT116 and LoVo 
cells grown in vitro or in vivo (Fig.4B, Fig.5C). From the input data we defined normal distributions 
by the measured means and standard deviations and applied bootstrapping to build ensembles of 1,000 
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cells for each treatment condition and cell line for both in vitro and in vivo scenarios. This allowed us 
to reflect the heterogeneity of large cell ensembles within the modelling framework and to simulate or 
predict the behaviour of cell populations in response to treatment in vitro and in vivo. 
 
Correlation of model predictions and drug effects on tumour growth  
Tumour growth inhibitory effects (ܭ஽) induced by the respective treatments were estimated from the 
in vivo tumour growth data. For this, we expressed the observed volume change over time (ௗ௏ௗ௧ ) from 
the difference between tumour growth when untreated and a treatment-mediated reduction in growth, 
with the latter being proportional to the tumour volume (3, 4): 
ܸ݀
݀ݐ ൌ ൞
ܸܽ ൬1 െ ܸܭ൰ ,																					ݐ ൏ ݐ௦௧௔௥௧	௧௥௘௔௧௠௘௡௧
ܸܽ ൬1 െ ܸܭ൰ െ ܭ஽ܸ, ݐ ൒ ݐ௦௧௔௥௧	௧௥௘௔௧௠௘௡௧
 
The tumour volume ܸሺݐሻ, when untreated, can be expressed as: 
ܸሺݐሻ ൌ ܭ ଴ܸ
଴ܸ ൅ ሺܭ െ ଴ܸሻ݁ି௔௧ 
where ଴ܸ indicates the volume of the individual tumours at time of first measurement (ܸሺݐ ൌ ݐ଴ሻሻ. The 
parameters ܭ and ܽ are cell-line specific constants representing the “carrying capacity” (maximal 
asymptotic growth) and the proliferation rate, respectively. We fitted each volume measurement (days 
5, 7, 9, 12, 14, 16, 19, 21, 23 and days 11, 13, 15, 18, 29, 22, 25, 27 for HCT116 and LoVo, 
respectively) using the MATLAB function lsqcurvefit with initial values for ଴ܸ ൌ 25	ሾ݉݉ଷሿ, ܽ ൌ
0.2	ሾ݀ܽݕିଵሿ, ܭ ൌ 300	ሾ݉݉ଷሿ and ܭ஽಴೚೙೟ೝ೚೗ ൌ ܭ஽ఱూ౑	శ	ో౮౗ౢ౟ ൌ ܭ஽౐ైయమళభభ ൌ ܭ஽ఱూ౑	శ	ో౮౗ౢ౟	శ	౐ైయమళభభ ൌ
0.01	ሾ݀ܽݕିଵሿ. 
We computed the mean and s.d. of the bootstrapped ܭ஽ across 1000 iterations as a measure of 
experimental treatment efficacy. For each cell line and treatment, we computed the fraction of the 
simulated cell ensemble that was modelled to undergo apoptosis (SC>25% at 72 h), (Fig.6A-B). 
Model-predicted cell death and drug effects on in vivo tumour growth (mean bootstrapped ܭ஽ሻ were 
then tested for correlation (Pearson and Spearman), (Fig.6G). 
Modelling code and associated data are available as a Zenodo repository 
(https://doi.org/10.5281/zenodo.1067500) 
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Supplemental Figure 1: Mathematical simulations of in vitro and in vivo apoptosis 
competency subsequent to MOMP. (A-D) The behaviour of ensembles of 1,000 cells per 
treatment condition was mathematically modelled for HCT116 cells in vitro (A) and in vivo 
(B) or LoVo cells in vitro (C) and in vivo (D). Cell ensembles were parameterised as 
described in the main manuscript. Each line represents the behaviour of one cell in the 
modelled ensemble. High amounts of substrate cleavage indicate that modelled cells are 
capable of executing apoptosis efficiently. Absent substrate cleavage or low amounts of 
substrate cleavage indicate failure to efficiently execute apoptosis. The simulation results 
indicate that post-MOMP heterogeneity is particularly prominent at in vivo conditions.  
